{"title": "Clinical trials", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2018-11-23", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|E.1 Medical condition or disease under investigation\n|\n|E.1.1||Medical condition(s) being investigated ||\n|\n|LTP syndrome.\n|\n|S\u00edndrome LTP\n|\n|E.1.1.1||Medical condition in easily understood language ||\n|\n|Alergia a nsLTP con s\u00edntomas graves en su respuesta frente a melocot\u00f3n, cacahuete, artemisia y olivo.\n|\n|Allergy to nsLTP with severe symptoms in response to peach, peanut, artemisia and olive.\n|\n|E.1.1.2||Therapeutic area ||Body processes [G] - Immune system processes [G12]\n|\n|MedDRA Classification\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||20.0\n|\n|E.1.2||Level ||PT\n|\n|E.1.2||Classification code ||10016946\n|\n|E.1.2||Term ||Food allergy\n|\n|E.1.2||System Organ Class ||10021428 - Immune system disorders\n|\n|E.1.3||Condition being studied is a rare disease || No\n|\n|E.2 Objective of the trial\n|\n|E.2.1||Main objective of the trial ||\n|\n|Evaluate the efficacy and safety of specific sublingual immunotherapy with Pru p 3 (SLIT-Prup3) in patients with allergy to nsLTP with severe symptoms in their response to peach, peanut, artemisia and olive trees by conducting controlled double-blind challenge with placebo (CDBCP) and/or specific nasal provocation test.\n|\n|Evaluar la eficacia y seguridad de la inmunoterapia sublingual especifica con Pru p 3 (ITSL-Prup3) en pacientes con alergia a nsLTP con s\u00edntomas graves en su respuesta frente a melocot\u00f3n, cacahuete, artemisia y olivo mediante la realizaci\u00f3n de prueba de provocaci\u00f3n doble ciego controlada con placebo (PPDCCP) y/oTPNE.\n|\n|E.2.2||Secondary objectives of the trial ||\n|\n|Monitor the immunological changes during the ITSL-Prup3 and after the completion (one year of treatment) of the same at different levels:\n|\na) In vivo: Evaluating changes in sensitization to peach, peanut, artemisia and olive trees, by analyzing the reactivity in intraepidermal tests with allergenic extracts, CDBCP against peach and peanut and by specific nasal provocation test against a p3 p, Art v 3, Ole e 7, artemisia and olive tree.\nb) In vitro:\nb.1) Humoral. Analyzing changes in the levels of IgE and IgG4 specific to different nsLTPs (Pru p 3, Ara h 9, Art v 3 and Ole e 7) as well as Art v 1 and Ole e 1 (major allergens of artemisia and olive tree) will be used to assess primary awareness of these pollens.\nb.2) Cellular. Assessing changes in CD maturation and in the proliferation of different effector and regulatory cell subpopulations specific to the different nsLTPs. The changes in subpopulation apoptosis will be analyzed.\n|Monitorizar los cambios inmunol\u00f3gicos durante la ITSL-Prup3 y tras la finalizaci\u00f3n (un a\u00f1o de tratamiento) de la misma a diferentes niveles:\n|\na) In vivo: Evaluando cambios en la sensibilizaci\u00f3n a melocot\u00f3n, cacahuete, artemisia y olivo, mediante el an\u00e1lisis de la reactividad en pruebas intraepid\u00e9rmicas con extractos alerg\u00e9nicos, PPDCCP frente a melocot\u00f3n y cacahuete y mediante TPNE frente aPru p 3, Art v 3, Ole e 7, artemisia y olivo.\nb) In vitro:\nb.1) Humoral. Analizando cambios en los niveles de IgE e IgG4 especificas a diferentes nsLTPs (Pru p 3, Ara h 9, Art v 3 y Ole e 7) as\u00ed como a Art v 1 y Ole e 1 (al\u00e9rgenos mayores de artemisia y olivo) que se utilizar\u00e1n para valorar sensibilizaci\u00f3n primaria a estos p\u00f3lenes.\nb.2) Celular. Evaluando cambios en la maduraci\u00f3n de CD y en la proliferaci\u00f3n de diferentes subpoblaciones celulares efectoras y reguladoras espec\u00edficas a las diferentes nsLTPs. Se analizar\u00e1n los cambios en apoptosis de subpoblaciones.\n|E.2.3||Trial contains a sub-study || No\n|\n|E.3||Principal inclusion criteria ||\n|\n|1. Informed Consent (IC) for the study and for the Biobank signed\n|\n2. Men or women \u22655 and \u226455 years of age.\n3. Moderate/severe allergic reaction after ingestion of peach, with or without peanut, confirmed by PPDCCP with peach.\n|1. Consentimiento informado (CI) del estudio y de Biobanco firmado\n|\n2. Hombres o mujeres entre 5 y 55 a\u00f1os de edad.\n3. Reacci\u00f3n al\u00e9rgica moderada/grave tras la ingesti\u00f3n de melocot\u00f3n acompa\u00f1ado o no de cacahuete, confirmado por PPDCCP con melocot\u00f3n.\n|E.4||Principal exclusion criteria||\n|\n|1. Pregnancy and lactation.\n|\n2. Immunological diseases, treatments with immunomodulators and/or blockers.\n3. Mental illness.\n4. Severe atopic dermatitis according to SCORAD (53)\n5. FEV1 <70%.\n6. Inflammation in the oral cavity with severe symptoms, oral surgery in the previous 7 days.\n|1. Embarazo y lactancia\n|\n2. Enfermedades inmunol\u00f3gicas, tratamientos con inmunomoduladores y/o bloqueantes.\n3. Enfermedad mental.\n4. Dermatitis at\u00f3pica grave seg\u00fan SCORAD (53)\n5. FEV1<70%.\n6. Inflamaci\u00f3n en cavidad oral con s\u00edntomas severos, cirug\u00eda oral en los 7 d\u00edas previos.\n7. IT con p\u00f3lenes en los 2 a\u00f1os anteriores o cualquier otra condici\u00f3n que contraindique la IT.\n8. Alergia a coco.\n9. Sujetos incapaces de realizar el tratamiento.\n|E.5 End points\n|\n|E.5.1||Primary end point(s)||\n|\n|Evaluation of the in vivo response\n|\n- Skin tests\n- Specific nasal provocation test\n- CDBCP with Peach and Peanut\n|Evaluaci\u00f3n de la respuesta in vivo\n|\n- Pruebas cut\u00e1neas\n- Test de provocaci\u00f3n nasal espec\u00edfica (TPNE)\n- PPDCCP con Melocot\u00f3n y Cacahuete\n|E.5.1.1||Timepoint(s) of evaluation of this end point||\n|\n|- Skin tests: Screening period, 1, 6 and 12 months of treatment.\n|\n- Specific nasal provocation test & CDBCP with Peach and Peanut: Screening period and 12 months.\n|- Pruebas cut\u00e1neas: Periodo de selecci\u00f3n (V0), al mes de inicio del tratamiento (V2), A los 6 meses (V3) y a los 12 meses de tratamiento (V4).\n|\n- Test de provocaci\u00f3n nasal espec\u00edfica (TPNE) y PPDCCP con Melocot\u00f3n y Cacahuete: Periodo de selecci\u00f3n (V0) y a los 12 meses de tratamiento (V4).\n|E.5.2||Secondary end point(s)||\n|\n|Sensibilizaci\u00f3n in vitro frente a Pru p 3, Ara h 9, Art v3, Ole e 7, Ole e 1 y Art v 1.\n|\n|Sensibilizaci\u00f3n in vitro frente a Pru p 3, Ara h 9, Art v3, Ole e 7, Ole e 1 y Art v 1.\n|\n|E.5.2.1||Timepoint(s) of evaluation of this end point||\n|\n|V0, V1, V2, V3 y V4\n|\nVisit 0 (Screening) , V1 (start of treatment) , V2 (1 month of treatment), V3 (6 months of treatment) and V4 (12 months of treatment)\n|V0, V1, V2, V3 y V4\n|\nPeriodo de selecci\u00f3n (V0), al inicio del tratamiento (V1), al mes del inicio del tratamiento (V2), a los 6 meses del inicio del tratamiento (V3) y a los 12 meses del inicio del tratamiento (V4).\n|E.6 and E.7 Scope of the trial\n|\n|E.6||Scope of the trial\n|\n|E.6.1||Diagnosis|| No\n|\n|E.6.2||Prophylaxis|| No\n|\n|E.6.3||Therapy|| No\n|\n|E.6.4||Safety|| Yes\n|\n|E.6.5||Efficacy|| Yes\n|\n|E.6.6||Pharmacokinetic|| No\n|\n|E.6.7||Pharmacodynamic|| No\n|\n|E.6.8||Bioequivalence|| No\n|\n|E.6.9||Dose response|| No\n|\n|E.6.10||Pharmacogenetic|| No\n|\n|E.6.11||Pharmacogenomic|| No\n|\n|E.6.12||Pharmacoeconomic|| No\n|\n|E.6.13||Others|| No\n|\n|E.7||Trial type and phase\n|\n|E.7.1||Human pharmacology (Phase I)|| No\n|\n|E.7.1.1||First administration to humans|| No\n|\n|E.7.1.2||Bioequivalence study|| No\n|\n|E.7.1.3||Other|| No\n|\n|E.7.1.3.1||Other trial type description||\n|\n|E.7.2||Therapeutic exploratory (Phase II)|| No\n|\n|E.7.3||Therapeutic confirmatory (Phase III)|| Yes\n|\n|E.7.4||Therapeutic use (Phase IV)|| No\n|\n|E.8 Design of the trial\n|\n|E.8.1||Controlled|| Yes\n|\n|E.8.1.1||Randomised|| Yes\n|\n|E.8.1.2||Open|| No\n|\n|E.8.1.3||Single blind|| No\n|\n|E.8.1.4||Double blind || Yes\n|\n|E.8.1.5||Parallel group|| Yes\n|\n|E.8.1.6||Cross over || No\n|\n|E.8.1.7||Other|| No\n|\n|E.8.2|| Comparator of controlled trial\n|\n|E.8.2.1||Other medicinal product(s)|| No\n|\n|E.8.2.2||Placebo || Yes\n|\n|E.8.2.3||Other|| No\n|\n|E.8.2.4||Number of treatment arms in the trial||2\n|\n|E.8.3||\nThe trial involves single site in the Member State concerned\n|| No\n|\n|E.8.4|| The trial involves multiple sites in the Member State concerned || Yes\n|\n|E.8.4.1||Number of sites anticipated in Member State concerned||3\n|\n|E.8.5||The trial involves multiple Member States|| No\n|\n|E.8.6 Trial involving sites outside the EEA\n|\n|E.8.6.1||Trial being conducted both within and outside the EEA|| No\n|\n|E.8.6.2||Trial being conducted completely outside of the EEA|| No\n|\n|E.8.7||Trial has a data monitoring committee|| No\n|\n|E.8.8||\nDefinition of the end of the trial and justification where it is not the last\nvisit of the last subject undergoing the trial\n||\n|\n|LVLS\n|\n|LVLS\n|\n\u00daltima visita del \u00faltimo sujeto.\n|E.8.9 Initial estimate of the duration of the trial\n|\n|E.8.9.1||In the Member State concerned years||1\n|\n|E.8.9.1||In the Member State concerned months||7\n|\n|E.8.9.1||In the Member State concerned days||\n|", "language": null, "image": null, "pagetype": null, "links": ["/help.html", "/ctr-search/search", "/joiningtrial.html", "/contacts.html", "/about.html", "/about.html", "/whatsNew.html", "/dataquality.html", "/doc/Sponsor_Contact_Information_EUCTR.pdf", "/natauthorities.html", "/links.html", "/index.html", "/about.html", "https://euclinicaltrials.eu/", "https://eudract.ema.europa.eu/docs/guidance/EudraCT%20FAQ_for%20publication.pdf", "/doc/How_to_Search_EU_CTR.pdf#zoom=100,0,0", "javascript:void(0)", "javascript:void(0)", "#", "javascript:$('#expand').click();window.print()", "javascript:void(0)", null, "javascript:window.location.replace('#A')", "javascript:window.location.replace('#B')", "javascript:window.location.replace('#C')", "javascript:window.location.replace('#D')", "javascript:window.location.replace('#D8')", "javascript:window.location.replace('#E')", "javascript:window.location.replace('#F')", "javascript:window.location.replace('#G')", "javascript:window.location.replace('#N')", "javascript:window.location.replace('#P')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", "https://eudract.ema.europa.eu/contact.html", "/disclaimer.html", "https://euclinicaltrials.eu/", "http://www.ema.europa.eu", "http://www.hma.eu"]}